Basildon (UK), 3 June 2021 – Pharmanovia, the original medicines specialist globally announced the promotion of Alessandro Insalata to Chief Commercial Officer (CCO) and his new position on the Executive team.
“Alessandro has been a key part of our recent success, and we were thrilled to promote him to this important position,” said Dr Amit Patel, CEO of Pharmanovia. “Alessandro joined the company in 2020 as Head of International and has overseen the development of our global commercialisation capabilities, which is key to delivering our stated objective of organic growth. This promotion and the new position on the Executive team reflects his dedication and success, as well as the importance of his team’s work. Our purpose is to progress iconic medicines for the global benefit of patient health, and we are confident that Alessandro will be an important asset to help our company reach its goals,” said Dr Patel.
Alessandro added: “I’m honoured by the trust that Amit, the Executive Team and the shareholders have given me, and in my appointment to Chief Commercial Officer. I’m also grateful for the hard work my team has put into strengthening our commercial capabilities. I look forward to further contributing to the growth of Pharmanovia’s global commercial infrastructure, and delivering medicines that patients, prescribers, healthcare providers and regulators value”.
Alessandro has extensive experience in the pharmaceutical industry, having led strategic commercial growth initiatives for both large and specialty multinationals at corporate level, including AstraZeneca, Concordia (now Advanz) and Dexcel Pharma. His background includes commercial, mergers and acquisitions, business development, in-licensing and portfolio development, with specific focus on Europe and Emerging Markets.
Alessandro graduated in Business and Economics at the Università degli Studi di Brescia and holds a Global MBA from Alliance Manchester Business School.
Connect with Alessandro on LinkedIn
About Pharmanovia – The original medicines specialist globally
Our purpose is to progress iconic medicines for the benefit of patient health globally.
We provide iconic, tried and trusted medicines in the strategic therapeutic areas of Cardiovascular, Women’s Health & Endocrinology, Neurology & Pain, and Gastroenterology & Oncology.
We own some of the world’s most recognisable brands, including Bonviva®, Kytril®, Inderal®, Naprosyn®, Valium®, Zestril® and more.
We operate a portfolio of 20+ brands in 140+ markets with over 200 employees, and we grow through development, licensing and acquisition.